Several of the resultant hypoxanthine-aminopterin-thymidine-resistant hybrid cell clones secreted a soluble product that significantly inhibited (>50%) IL-2-dependent T cell proliferation when tested in conventional T cell growth factor microassays (4) . Of the potential anti-IL-2 secreting hybridomas, the clone designated 4E 12B2H5 was selected for further characterization based on the capacity of this cell line's supernate to totally inhibit IL-2-dependent T cell line proliferation. In fact, when tested at a dilution of 1:20 in the presence of the co-precipitating matrix Igsorb (The Enzyme Center, Boston, Mass.), 4E 12B2H5 culture supernate completely abrogated tritiated thymidine ([3H]TdR) incorporation of T cell lines as monitored after 24-h culture in the presence of 3 U/ml IL-2 (1) .
Peritoneal ascites containing large concentrations of anti-IL-2 antibody were produced by intraperitoneal challenge of BALB/c female mice (6-8 wk of age, from the Central Animal Facility, Fred Hutchinson Cancer Research Center) with 2 X 106 4E12B2H5 hybridoma cells. Mice were challenged 1 wk after intraperitoneal injection with 0.5 ml of pristane (Baker Chemical Co., Seattle, Wash.). 10-14 d after the administration of4E12B2H5 hybridoma cells, intraperitoneal ascites were harvested, clarified by centrifugation, and frozen (-20°C) until used for purification of anti-IL-2 IgG.
IgG purification was achieved by successive binding/elution from protein A-coupled Sepharose (Pharmacia Fine Chemicals, Piscataway, N. J.). 3-5 ml of hybridoma ascites was passed over a 10-ml protein A-Sepharose column equilibrated in 0.9% NaCI. Anti-IL-2 IgG was removed from the column by elution with 200 mM glyeine HC1 buffer, pH 3. Purified antibody was then dialyzed overnight against 1,000 vol of 0.9% NaCI Hepes, pH 7. [aH]TdR incorporation of CTLL-2 ceils. In the absence of anti-IL-2 or in the presence of parent myeloma SP-2 cell-conditioned medium, CTLL-2 cells cultured in the presence of 3 U/ml IL-2 (with or without Igsorb) incorporated maximal amounts of [3H]TdR during a 4-h pulse some 20 h after culture initiation. However, in the presence of a 1:20 dilution of crude 4E12B2H5 hybridoma culture supernate, IL-2-induced [3H]TdR incorporation was markedly inhibited. Similar levels of inhibition were observed in CTLL-2 cell cultures containing IL-2 and 4E12B2H5 hybridomaderived IgG (purified by protein-A Sepharose affinity chromatography). Greater than 90% inhibition of proliferation was observed in cultures containing either 10 or 1 ptg/ ml of4E12B2H5 IgG, whereas 10/~g/ml of anti-gp70 IgG in identical cultures had no effect on IL-2-driven CTLL-2 cell replication.
Monoclonal Anti-IL-2 IgG Inhibition of T Cell Mitogenesis.
Given (a) the capacity of monoclonal 4E12B2H5 antibody to inhibit IL-2-dependent T cell proliferation in both neutralizing and precipitating (in concert with Igsorb) cultures and (b) the hypothesis that IL-2 is the driving force behind normal mitogen-induced T cell proliferation (2, 7, 8) , we were curious to determine what effect anti-IL-2 IgG would have on Con A-induced T cell mitogenesis. As shown in Table I , inclusion of anti-IL-2 IgG in cultures of Con A-stimulated normal murine spleen cells severely inhibited resultant T cell proliferation as assessed by [3H]TdR incorporation during hours 72-76 in culture. Significant inhibition was observed with <1 ~g/ml of 4E12B2H5 IgG. However, Con A stimulation conducted either in the absence of anti-IL-2 or in the presence of 20 #g/ml of anti-gp70 IgG resulted in splenoeyte stimulation indices >25 times the background [3H]TdR incorporation observed.
As was repeatedly seen in assays testing the effect of anti-IL-2 on T cell line proliferation, the ability of anti-IL-2 IgG to inhibit mitogenesis was dose-dependent and enhanced in Igsorb-containing cultures. The capacity of the Igsorb reagent to augment inhibition of mitogenesis parallels our previous observation using anti-IL-2 to inhibit the proliferation of an IL-2-dependent T cell line (1). Collectively considered, these data suggest that 4E12B2H5 hybridoma produces an anti-IL-2 antibody with reactivity directed against determinants distal to the biologically active site of the lymphokine.
Effect of Anti-IL-2 on the MLC Generation of Alloreactive CTL.
Based on the ability of anti-IL-2 IgG to inhibit T cell mitogenesis, we asked whether similar addition of 4E12B2H5 hybridoma antibody to MLC would result in decreased generation of cytolytic effector cell reactivity. As detailed in Fig. 2 , addition of anti-IL-2 (at concentrations as low as 1 /.tg/ml) at the initiation of alloantigen-stimulated C57BL/6 spleen cell cultures markedly inhibited resultant effector cell reactivity as monitored 5 d later in 4-hour SlCr release assays. As was observed in mitogenesis experimentation, the ability of anti-IL-2 to inhibit MLC-driven CTL differentiation was dose-dependent and was more effective in cultures conducted in the presence of a co-precipitating matrix ( Fig. 2 ; Table II ).
The data displayed in Table II also detail the deleterious effect that addition of 4E12B2H5 IgG had on the recovery of viable effector cells from MLC. Therefore, not only did anti-IL-2 serve to depress the lytic activity of CTL generated in MLC, but also significantly curtailed proliferation and recovery of responsive T cells. In contrast to the results obtained when cultures were supplemented with anti-IL-2 IgG, the addition of an irrelevant anti-gp70 immunoglobulin had no effect on the lytic reactivity of alloreactive CTL generated (even when tested at antibody concentrations as high as 40 ~g/ml) or on viable cell recovery (Table II) .
Discussion
The results presented in this communication have detailed the capacity of a monoclonal IgG antibody directed against a determinant present on IL-2 to severely inhibit several proliferation-dependent in vitro T cell immune responses. In addition to curtailing II-2-dependent T cell line proliferation, the addition of the 4E12B2H5 IgG reagent to spleen celt cultures markedly inhibited both Con A-induced T cell mitogenesis and alloantigen-indueed generation of CTL. The ability of anti-IL-2 monoclonal antibody to inhibit these responses provides strong serological evidence that the production and use of IL-2 is essential for mitogen-induced T cell proliferation Based on the data presented above, it would appear that in addition to being a potentially useful reagent for IL-2 radioimmunoassays and affinity purification of IL-2, anti-IL-2 IgG may be of importance in dissecting the involvement of IL-2 in a number of disease states, most notably hyperimmune syndromes and T cell malig-nancy. In this regard it is interesting to note that the coupling of fluorescein to anti-IL-2 monoclonal antibody has resulted in the generation of an interesting reagent, which, when tested in cytoplasmic fluorescence assays, specifically stains only IL-2 producer cells (S. Gillis and D. Stull, unpublished observations). Finally, as indicated by its capacity to dramatically dampen mitogen-induced T cell replication and alloantigen-triggered CTL responses, it is conceivable that antibody directed against determinants present on the IL-2 molecule may function as an immunosuppressive drug. Such a reagent may be of value if indeed antigen-induced IL-2 production is a feature in aggravating hyperimmune disorders.
Summary
Our recent studies have detailed the generation of B cell hybridomas whose IgG product significantly inhibits interleukin 2 (IL-2)-dependent T cell replication. Given the capacity of such hybridoma antibody to interfere with the activity of mouse, rat, and human IL-2, we asked whether anti-IL-2 IgG would mediate similar inhibitory effects on other in vitro immune responses. In this communication, we report that addition of purified anti-IL-2 monoelonal antibody to either mitogen-or alloantigenstimulated spleen cells exerted markedly deleterious effects on both resultant T cell proliferation and the generation of cytolytic effector cells. These results provide serological evidence in support of the integral role that IL-2 plays in controlling antigen/mitogen-induced T cell proliferation and serves further to define the ability of monoclonal antibody against IL-2 to function as an immunosuppressive agent.
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